

DAFTAR PUSTAKA

1. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. *Gerontology*. 2019;65(5):458–64.
2. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? *BJU International*. 2021;127(4):389–99.
3. Radej S, Szewc M, Maciejewski R. Prostate infiltration by treg and th17 cells as an immune response to propionibacterium acnes infection in the course of benign prostatic hyperplasia and prostate cancer. *International Journal of Molecular Sciences*. 2022;23(16):8849.
4. Partin AW, Dmochowski RR, Kavoussi LR, Peters CA. *Campbell-Walsh-Wein Urology*. 12th ed. Elsevier;2021.
5. Cai T, Santi R, Tamanini I, Galli IC, Perletti G, Bjerklund Johansen TE, et al. Current knowledge of the potential links between inflammation and prostate cancer. *International Journal of Molecular Sciences*. 2019;20(15):3833.
6. Mathey LIP. Benign prostatic hyperplasia: epidemiology, pathophysiology, and clinical manifestations. In: Budak M, Rajkumar R. *Molecular mechanisms in cancer*. 1st ed. IntechOpen; 2022.
7. Langan RC. Benign prostatic hyperplasia. *Primary Care - Clinics in Office Practice*. 2019;46(2): 223–32.
8. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. *Laporan nasional Riskesdas 2018*. Jakarta; 2019.
9. Mulyadi HTS, Sugiarto S. Prevalensi hiperplasia prostat dan adenokarsinoma prostat secara histopatologi di laboratorium patologi anatomi rumah sakit umum daerah cibinong. *Muhammadiyah Journal of Geriatric*. 2020;1(1):12.

10. Nahid S, Sultana M, Saiham KS, Afrin R, Yesmin L, Mohammed N, et al. Transabdominal ultrasonographic evaluation of enlarged prostate with histopathological comparison. *Scholars Journal of Applied Medical Sciences*. 2022;10(4):562–6.
11. Lerner LB, Mcvary KT, Barry MJ, Anurag, Das K, Gandhi MC, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I—Initial work-up and medical management. *Journal of Urology*. 2021;206(4):806–17
12. Aigbe E, Irekpita E, Ogbetere F, Alili U. Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia. *Nigerian Journal of Clinical Practice*. 2022;25(9):1523
13. Padmapriya BS, Harikrishnan V. Correlation between prostate specific antigen (PSA) level and various prostatic diseases on biopsies: a retrospective study. *Journal of Pharmaceutical Research International*. 2021;33(63b):105–10.
14. Cinislioglu AE, Demirdogen SO, Cinislioglu N, Altay MS, Sam E, Akkas F, et al. Variation of serum PSA levels in COVID-19 infected male patients with benign prostatic hyperplasia (BPH): a prospective cohort study. *Urology*. 2022;159:16–21.
15. Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. *Mediators of Inflammation*. 2020;2020:1–7.
16. Coban S, Doluoglu OG, Keles I, Demirci H, Turkoglu AR, Guzelsoy M, et al. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. *The Aging Male*. 2016;19(2):124–7.
17. Duvedi P, Singh H, Bedi GK, Kaur M. Role of prostate-specific antigen (PSA) in patients with benign prostate hyperplasia. *Journal of Clinical and Diagnostic Research*. 2019;13(5):BC01-BC03

18. Xue B, Wu S, Sharkey C, Tabatabaei S, Wu CL, Tao Z, et al. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. *Prostate Cancer and Prostatic Diseases*. 2020;23(3):465–74.
19. Xia B, Zhao S, Chen Z, Chen C, Liu T, Yang F, et al. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. *The Prostate*. 2020;80(6):481-90.
20. Li J, Peng L, Cao D, Gou H, Li Y, Wei Q. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis. *The Aging Male*. 2020;23(5):1388-99.
21. Wu S, He H, Wang Y, Xu R, Zhu B, Zhao X. Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a meta-analysis. *Journal of International Medical Research*. 2019;47(11):5389-99.
22. Ittmann M. Anatomy and histology of the human and murine prostate. *Cold Spring Harbor Perspective in Medicine*. 2018;8(5): a030346.
23. Singh O, Bolla SR. Anatomy, abdomen and pelvis, prostate. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK540987/> – Accessed March 2023.
24. Sklinda K, Frączek M, Mruk B, Walecki J. Normal 3T MR anatomy of the prostate gland and surrounding structures. *Advances in Medicine*. 2019;2019:1–9.
25. Duarsa GWDP, Sutawinata AA, Damayanti TA. Hubungan antara lower urinary tract symptoms (LUTS) dengan usia, diabetes melitus, dan hipertensi di Desa Menanga, Karangasem, Bali. *Medicina*. 2019;50(1):189–92.

26. Tjahjodjati, Soebadi DM, Umbas R, Mochtar CA, Daryanto B, Noegroho BS, et al. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak. 4th ed. Ikatan Ahli Urologi Indonesia; 2021.
27. Haghpanah A, Masjedi F, Salehipour M, Hosseinpour A, Roozbeh J, Dehghani A. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. *Prostate Cancer and Prostatic Diseases*. 2022;25(1): 27–38.
28. Miao L, Jiao C, Shao R, Qi Y, Fan G, Li X, et al. Bakuchiol suppresses oestrogen/testosterone-induced benign prostatic hyperplasia development through up-regulation of epithelial estrogen receptor β and down-regulation of stromal aromatase. *Toxicology and Applied Pharmacology*. 2019;381(1): 114637.
29. Chen W, Pascal LE, Wang K, Dhir R, Sims AM, Campbell R, et al. Differential impact of paired patient-derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture. *The Prostate*. 2020;80(14):1177–87.
30. Amadea RA, Langitan A, Wahyuni RD. Benign prostatic hyperplasia (BPH). *Jurnal Medical Profession (MedPro)*. 2019;1(2):172–76.
31. Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. *Journal of Urology*. 2019;202(3):592–8.
32. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C., et al. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). *European Association of Urology*; 2022.
33. Ng M, Baradhi KM. Benign Prostatic Hyperplasia. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK558920/> – Accessed March 2023.

34. Ramadhanurrosita N, Soebhali B, Nugroho H. The correlation of international prostate symptom score (IPSS) with Qmax on uroflowmetry of benign prostatic hyperplasia (BPH) patients at Abdul Wahab Sjahranie hospital in Samarinda. *Jurnal Ilmu Kesehatan*. 2019;7(2):85–91.
35. Abboudi H, Kalsi J, Aho T. Benign prostatic hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS). In: Arya M, Shah TT, Kalsi JS, Fernando HS, Shergill IS, Muneer A, et al. *MCQs for the FRCS(Urol) and Postgraduate Urology Examinations*. 1st ed. Boca Raton: CRC Press; 2022. p. 139–46.
36. Kusuma Duarsa GW, Sari YA, Gde Oka AA, Santosa KB, Yudiana IW, Wisnu Tirtayasa PM, et al. Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients. *Asian Journal of Urology*. 2021;8(3):289–97.
37. Duarsa GWK, Dau DO, Pramana IBP, Tirtayasa PMW, Yudiana IW, Santosa KB, et al. Risk factors for prostate volume progression after prostate-transurethral resection. *Research and Reports in Urology*. 2020;12:175–8.
38. Higgins J, Thomas J. *Cochrane Handbook for Systematic Reviews of Interventions* [Internet]. Willey; 2023 [February 24th 2024]. Available from: <https://training.cochrane.org/handbook/current>
39. Wibowo A, Putri S. *Pedoman Praktis Penyusunan Naskah Ilmiah dengan Metode Systematic Review*. 1st ed. Depok: Fakultas Kesehatan Masyarakat Universitas Indonesia; 2021.
40. Andriani W. Penggunaan metode sistematik literatur review dalam penelitian ilmu sosiologi. *Jurnal PTK dan Pendidikan*. 2021;7(2):124-33.
41. Roever L. PICO: Model for clinical questions. *Evidence based medicine and practice*. 2018;3(2).
42. Nursalam. *Literature Sytematic Review Pada Pendidikan Kesehatan*. Surabaya: Fakultas Keperawatan Universitas Airlangga; 2020.

43. Ikatan Ahli Urologi Indonesia. Pembesaran prostat jinak [internet]. [February 24th 2024]. Available from: <https://iaui.or.id/>
44. Nursalam. *Literature Sytematic Review Pada Pendidikan Kesehatan*. Surabaya: Fakultas Keperawatan Universitas Airlangga; 2020.
45. Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of software to support multiple systematic review types: The Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). *International Journal of Evidence-Based Healthcare*. 2019;17(1):36-43.
46. Zeng XT, Weng H, Xiong J, Huang Q, Ma LL, Jin YH, et al. Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients. *Frontiers in Physiology*. 2018;9:1-7.
47. Avci S, Onen E, Caglayan V, Kilic M, Sambel M, Oner S. Free Prostate-Specific Antigen Outperforms Total Prostate-Specific Antigen as a Predictor of Prostate Volume in Patients Without Prostate Cancer. *Archivio Italiano di Urologia e Andrologia*. 2020;92(1):1-6.
48. Mampa E, Haffejee M, Fru P. The Correlation Between Obesity and Prostate Volume in Patients with Benign Prostatic Hyperplasia at Charlotte Maxeke Johannesburg Academic Hospital. *African Journal of Urology*. 2021;27(60).
49. Levissa NRC, Rahman EY, Pratiwi DIN, Prasetya H, Kaidah S. Correlations of Prostate Volume with PSA Levels in BPH Patients at Ulin General Hospital Banjarmasin. *Berkala Kedokteran*. 2021;17(1):15-22.
50. Jung JW, Yu YD, Lee YJ, Kim JJ, Lee HM, Oh JJ, et al. Does Prostate-Specific Antigen (PSA) Mass or Free PSA Mass Improve the Accuracy of Predicting Total Prostate Volume in Relation to Obesity in Men with Biopsy-Proven Benign Prostatic Hyperplasia? *Asian Journal of Andrology*. 2019;21(1):86-91.

51. Xu XH, Xu ZH, Yuan MZ, Guan Y, Zhao ST. Effect of Prostate Volume on f/tPSA Value: A Cross-Sectional Study. *Andrologia*. 2021;53:e13851.
52. Huang MP, Tang P, Klein CS, Wei XH, Du W, Fu JG, et al. Free PSA Performs Better Than Total PSA in Predicting Prostate Volume in Chinese Men with PSA Levels of 2.5–9.9 ng ml⁻¹. *Asian Journal of Andrology*. 2023;25(1):82-5.
53. Fadila AN, Rahaju AS, Tarmono. Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH). *Qanun Medika*. 2020;4(2):171-7.
54. Abotsi E, Adanu KK, Bansah EC. Serum Prostate Specific Antigen is a Good Indicator of Prostatic Volume in Men with Benign Prostatic Hyperplasia. *African Journal of Primary Health Care & Family Medicine*. 2022;14(1):a3736.
55. Bezinque A, Moriarity A, Farrell C, Peabody H, Noyes SL, Lane BR. Determination of Prostate Volume: A Comparison of Contemporary Methods. *Academic Radiology*. 2018;25(12):1582-7.
56. Calogero AE, Burgio G, Condorelli RA, Cannarella R, Vignera SL. Epidemiology and risk factors of lower urinary tract symptoms/benignprostatic hyperplasia and erectile dysfunction. *The Aging Male*. 2019;22(1):12-9.
57. Perez-Ibave DC, Burciaga-Flores CH, Elizondo-Riojas MA. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. *Cancer Epidemiology*. 2018;54:48-55.
58. Li F, Yin X, Li D, Yin Z, Qi S, Shi H, et al. Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen. 2015;35(12):1721-4.
59. Christie DRH, Windsor J, Sharpley CF. A systematic review of the accuracy of the digital rectal examination as a method of measuring prostate gland volume. *Journal of Clinical Urology*. 2019;12(5):361-70.

60. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, *Jpn J Clin Oncol.* 2009;39: 468–9.

